Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan in Immune-Mediated Necrotizing Myopathy
NCT04025632Phase 2Terminated
- Sponsor
- Ra Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Mar 2021
- Modality
- Cyclic Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of zilucoplan in immune-mediated necrotizing myopathy (IMNM), sponsored by Ra Pharmaceuticals. Started Nov 2019; status: terminated.
02
Drugs
zilucoplan
03
Conditions
immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NCT04025632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025632.